Corient Private Wealth LLC Has $73.88 Million Stock Position in Gilead Sciences, Inc. $GILD

Corient Private Wealth LLC lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 601,849 shares of the biopharmaceutical company’s stock after purchasing an additional 30,144 shares during the period. Corient Private Wealth LLC’s holdings in Gilead Sciences were worth $73,877,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Brighton Jones LLC raised its holdings in shares of Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 2,450 shares during the period. Bison Wealth LLC bought a new position in Gilead Sciences during the fourth quarter worth about $215,000. Sivia Capital Partners LLC grew its holdings in Gilead Sciences by 16.8% during the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after purchasing an additional 602 shares during the period. Ieq Capital LLC increased its position in Gilead Sciences by 12.0% during the second quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock worth $13,160,000 after buying an additional 12,705 shares during the last quarter. Finally, Diversify Advisory Services LLC increased its position in Gilead Sciences by 18.6% during the second quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock worth $516,000 after buying an additional 674 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on GILD shares. Royal Bank Of Canada reaffirmed a “sector perform” rating on shares of Gilead Sciences in a research report on Monday, June 8th. Daiwa Securities Group dropped their price target on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 19th. Needham & Company LLC reaffirmed a “buy” rating and set a $170.00 price target on shares of Gilead Sciences in a report on Monday, February 23rd. Jefferies Financial Group assumed coverage on shares of Gilead Sciences in a research report on Tuesday, March 10th. They set a “buy” rating and a $180.00 price objective for the company. Finally, Weiss Ratings lowered shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, May 28th. Twenty-five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $158.41.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the transaction, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. This trade represents a 1.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the sale, the insider owned 125,779 shares of the company’s stock, valued at approximately $16,513,524.91. The trade was a 18.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 68,000 shares of company stock worth $8,930,150 in the last quarter. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Price Performance

GILD opened at $123.76 on Friday. Gilead Sciences, Inc. has a fifty-two week low of $104.46 and a fifty-two week high of $157.29. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The company has a market capitalization of $153.66 billion, a P/E ratio of 16.86 and a beta of 0.31. The stock has a fifty day moving average of $131.66 and a 200-day moving average of $134.21.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same period in the prior year, the company posted $1.81 earnings per share. Gilead Sciences’s revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, equities analysts expect that Gilead Sciences, Inc. will post -0.8 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s dividend payout ratio is presently 44.69%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.